<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032235</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3162-I-119</org_study_id>
    <nct_id>NCT05032235</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function</brief_title>
  <official_title>A Multi-centre, Open-label and Parallel-control Study to Investigate the Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate pharmacokinetics of Fluzoparib and its main metabolite&#xD;
      in subjects with impaired kidney function in comparison with healthy subjects, to develop&#xD;
      dose recommendations for patients with renal impairment.&#xD;
&#xD;
      The secondary objective is to evaluate the safety of Fluzoparib in subjects with mild and&#xD;
      moderate renal impairment and in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">October 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single dose of oral administration of Fluzoparib</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of Fluzoparib: Cmax</measure>
    <time_frame>96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of Fluzoparib: AUC0-t</measure>
    <time_frame>96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of Fluzoparib: AUC0-∞ (if available)</measure>
    <time_frame>96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: Cmax</measure>
    <time_frame>96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: AUC0-t</measure>
    <time_frame>96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: AUC0-∞ (if available)</measure>
    <time_frame>96 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetics parameters of Fluzoparib: Tmax</measure>
    <time_frame>96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: Tmax</measure>
    <time_frame>96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein binding rate of Fluzoparib</measure>
    <time_frame>Day 01 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein binding rate of main metabolite (SHR165202) of Fluzoparib</measure>
    <time_frame>Day 01 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events (based on NCI-CTCAE 5.0)</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Normal Renal Function:A single oral dose of Fluzoparib will be administered.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Inclusion Criteria for subjects with impaired kidney function:&#xD;
&#xD;
          1. Sign the informed consent before the trial, and fully understand the content, process,&#xD;
             and possible adverse reactions of the trial;&#xD;
&#xD;
          2. Male or female subjects aged 18 to 70 (including 18 and 70);&#xD;
&#xD;
          3. Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28);&#xD;
&#xD;
          4. The glomerular filtration rate should meet the following criteria (GFR,&#xD;
             mL/min):Subjects with mild renal impairment (CKD2): 60-89 mL/min (including&#xD;
             60-89);Subjects with moderate renal impairment (CKD3): 30-59 mL/min (including 30-59&#xD;
             ends);&#xD;
&#xD;
          5. Renal function should be stable, and the GFR results should be tested twice before&#xD;
             administration (at least 3 days apart) within the same CKD stage.&#xD;
&#xD;
        Inclusion Criteria for subjects with normal kidney function:&#xD;
&#xD;
          1. Sign the informed consent before the trial and fully understand the content, process,&#xD;
             and possible adverse reactions of the trial;&#xD;
&#xD;
          2. Male or female subjects aged 18 to 70 (including 18 and 70);&#xD;
&#xD;
          3. Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28);&#xD;
&#xD;
          4. Glomerular filtration rate (GFR) ≥90 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria for subjects with impaired kidney function:&#xD;
&#xD;
          1. History of kidney transplant;&#xD;
&#xD;
          2. Need Renal dialysis during the study;&#xD;
&#xD;
          3. Urinary incontinence or anuria;&#xD;
&#xD;
          4. Clinically significant heart disease, including but not limited to: congestive heart&#xD;
             failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms&#xD;
             (female) or QTcF≥450 ms (male) within 12 months before the start of treatment;&#xD;
&#xD;
          5. Received any investigational drug within 3 months before the study started;&#xD;
&#xD;
          6. Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the&#xD;
             study started;&#xD;
&#xD;
          7. Smokers and alcoholics, or those screened positive for alcohol;&#xD;
&#xD;
          8. History of drug use, or drug abuse screening positive.&#xD;
&#xD;
        Exclusion Criteria for subjects with normal kidney function:&#xD;
&#xD;
          1. History of kidney transplant;&#xD;
&#xD;
          2. Clinically significant heart disease, including but not limited to: congestive heart&#xD;
             failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms&#xD;
             (female) or QTcF≥450 ms (male) within 12 months before the start of treatment;&#xD;
&#xD;
          3. Received any investigational drug within 3 months before the study started;&#xD;
&#xD;
          4. Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the&#xD;
             study started;&#xD;
&#xD;
          5. Smokers and alcoholics, or those screened positive for alcohol;&#xD;
&#xD;
          6. History of drug use, or drug abuse screening positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuya Wang, Ph.D</last_name>
    <phone>13918749176</phone>
    <email>yuya.wang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Rao, M.M</last_name>
    <phone>17612186457</phone>
    <email>jing.rao@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

